Skip to main content
Aptamer Sciences Inc logo

Aptamer Sciences Inc — Investor Relations & Filings

Ticker · 291650 ISIN · KR7291650000 KO Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2022-10-06 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 291650

About Aptamer Sciences Inc

https://aptsci.com/en/

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in aptamer technology. The company has established a proprietary, integrated platform for the discovery and development of aptamer-based therapeutics and diagnostics. Its primary focus is on oncology, utilizing its Aptamer-Drug Conjugate (ApDC™) platform to create targeted cancer treatments. The lead candidate, AST-201, is an ApDC targeting the GPC3 protein, which is highly expressed in solid tumors such as liver cancer. The company is advancing AST-201 through clinical trials to evaluate its safety and efficacy. The development pipeline also includes other innovative platforms like Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS), aimed at addressing unmet medical needs in hemato-oncology and other areas. Aptamer Sciences leverages its technology to develop novel therapies with the potential for high specificity and efficacy.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시)(제1회차 CB)
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a convertible bond, or CB). It details the issuance amount, payment date, and the nature of the security. This falls under the category of capital and financing updates, specifically related to the issuance of debt instruments.
2022-10-06 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding the issuance of convertible bonds (전환사채권 발행결정) by Aptamer Science. This is a formal regulatory filing submitted to the Financial Supervisory Service/Korea Exchange, detailing the terms of the financing, including interest rates, conversion prices, and the use of proceeds. This falls under the category of capital and financing updates.
2022-10-04 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '주식회사 압타머사이언스' covering the period from 2022.01.01 to 2022.06.30. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-16 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company '주식회사 압타머사이언스' (Aptamer Sciences Inc.) covering the period from 2022.01.01 to 2022.03.31. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders to disclose changes in their shareholdings. This corresponds to the 'Director's Dealing' category, which covers insider trades and changes in ownership by company directors and executives.
2022-04-12 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment, dismissal, or resignation of an outside director (사외이사). This falls under the category of board or management changes.
2022-03-29 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.